Sanofi's (SNY) plans to seperate its consumer care unit draws buyout bids with over €10B in funding committed from banks and ...

Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on Sanofi (SNYNF – Research Report) and increased the price target ...

Sanofi Chief Executive Paul Hudson said on Monday that the company has not made a final decision yet on how it plans to split ...

The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...

This summary highlights major health news, including EU's endorsement of Novo Nordisk's Wegovy for heart conditions in ...

The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end ...

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...